What question did this study set out to answer?

This study aims to evaluate pharmacokinetics and exposure–response relationships of durvalumab in stage II to IIIB NSCLC patients.

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

View Full Paper

Ask AI

Bookmark

Authors

Population pharmacokinetics analysis reveals efficacy of perioperative durvalumab in resectable NSCLC, indicating minimal impact on safety.

This study aims to evaluate pharmacokinetics and exposure–response relationships of durvalumab in stage II to IIIB NSCLC patients.
Updated the durvalumab PopPK model with PK data from the AEGEAN study.
Estimated individual exposure metrics for exposure–response analyses related to safety and efficacy.
Analyzed dose levels, clearance, and volume of distribution using a two-compartment model.
The two-compartment model characterized durvalumab pharmacokinetics adequately.
Observed relationships between durvalumab pharmacokinetics and event-free survival, confirmed by Cox proportional hazards analysis.
No clinically relevant impact on safety endpoints from durvalumab pharmacokinetics.

Zhao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Population pharmacokinetics analysis reveals efficacy of perioperative durvalumab in resectable NSCLC, indicating minimal impact on safety.